CD8A and cancer: Across multiple cancer types, including melanoma, glioma, and NSCLC, as well as ovarian, bladder, and breast cancers [125], high intra-tumoral densities of CD8+CD103+ TILs were also identified as predictive biomarkers for ICI response, therapeutic cancer vaccines, and clinical outcome.